AMSBIO announces ClioCell™ an ex-vivo device for removal of dying and dead cells, improving viability and quality of cell populations and their subsequent productivity.

The system comprises super-paramagnetic nanoparticles which have been coupled with proprietary elements that bind to dead and dying cells and cell debris. The resultant product selectively initiates dead-cell removal, emulating dead-cell clearance mechanisms which operate in-vivo to keep tissues functioning optimally. This technology is step-changing, providing new opportunities to optimise cell growth, culture and storage.

ClioCell™ has a broad array of uses, spanning a number of diverse academic and industrial applications. The ability to selectively remove inhibitory or toxic dead cells using a simple and rapid procedure results in radically improved cell populations; specifically, with regard to viability antibody/protein yield and consequent functional efficacy. ClioCell™ has been evaluated by several leading independent commercial and academic research institutions working on cell culture projects.  It has been successfully tested on many cell types, both human and mammalian. Cliocell™ can be manufactured to cGMP grade and our team has experience of many cell types, pre and post thaw applications and "Big Pharma" project work.

more about amsbio cliocell

more news from amsbio

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology products and services for research and development in the medical, nutrition, cosmetics and energy industries. The AMSBIO range includes specialist antibodies, peptides and recombinant proteins. In addition the company is able to draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as experts in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance screening outcomes and eventual prognosis. With a range of molecular detection reagents, and a significant Biorepository the company can also provide tissue DNA, RNA, protein and microarray products. Key research areas for these products include: Oncology, Regenerative Medicine, Environmental Analysis, Cytotoxicity Screening, Glycomics and Stem Cell Biology.